Leading therapeutic innovation in pregnancy to deliver healthy beginnings

Livmor develops treatments for fetal protection and the prevention of preterm birth. Based on decades of research in pregnancy physiology, these therapeutics interrupt inflammation during pregnancy, protecting fetal organ development and ensuring a healthy start to life.

Livmor’s breakthrough treatment addresses fetal inflammation and the underlying causes of preterm birth

Our innovative approach aims to provide a safer and more effective solution for mothers and babies. We are working hard to make Livmor’s therapy available soon.

Our team

Our team is committed and driven to implementing innovative solutions that transform pregnancy health and address the challenges of fetal inflammation and preterm birth.

David Olson PhD DSc, FRCOG, FCAHS

President

Sylvain Chemtob, MD, PhD, FRCPC, FAAP, FCAHS, FRSC

Chief Scientific Officer

Kelycia Leimert,
BSc, PhD

Senior Scientist – Operations

Christiane Quiniou,
PhD, MBA

Senior Scientist – Therapeutic Design